表紙
市場調査レポート

再発性多発性骨髄腫:世界の治験レビュー

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 304740
出版日 ページ情報 英文 121 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
再発性多発性骨髄腫:世界の治験レビュー Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2014
出版日: 2014年10月31日 ページ情報: 英文 121 Pages
概要

当レポートでは、再発性多発性骨髄腫に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、治験における主要国、G7諸国およびE7(新興7カ国)における治験数および被験者採用の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報をまとめてお届けします。

目次

イントロダクション

  • 再発性多発性骨髄腫
  • 当レポートの概要

各地域における治験状況

各国の治験件数と平均被験者数

  • アジア太平洋地域の上位5ヶ国における治験件数
  • 欧州上位5ヶ国における治験件数
  • 北米の主要国における治験件数
  • 中東およびアフリカの主要国における治験件数
  • 中南米の上位5ヶ国における治験件数

G7諸国での治験件数:がんの治験件数に対する再発性多発性骨髄腫の比率

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7(新興7カ国)における治験件数:がんの治験件数に対する再発性多発性骨髄腫の比率

E7(新興7カ国)での治験件数:フェーズ(相)別

E7(新興7カ国)での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

エンドポイント達成状況別の治験件数

未達成の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

有望な薬剤

最新の治験情報

治験のプロファイル

  • 代表的企業の治験の概要
    • Celgene Corporation
    • Amgen Inc.
    • Johnson & Johnson
    • 武田薬品工業
    • Novartis AG
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Array BioPharma Inc.
    • AbbVie Inc.
  • 代表的な研究機関・病院の治験の概要
    • National Cancer Institute
    • Mayo Clinic
    • The University of Texas M. D. Anderson Cancer Center
    • Memorial Sloan Kettering Cancer Center
    • University of Arkansas
    • Washington University School of Medicine
    • Beijing Chao Yang Hospital
    • Fondazione Neoplasie Sangue Onlus
    • Massachusetts General Hospital

5つの代表的な治験のプロファイル

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC2387CTIDB

GlobalData's clinical trial report, "Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2014" provides data on the Relapsed Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsed Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Relapsed Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Relapsed Multiple Myeloma
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Relapsed Multiple Myeloma
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Relapsed Multiple Myeloma Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Relapsed Multiple Myeloma
    • Aug 29, 2014: Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study
    • Aug 13, 2014: Amgen Announces Top-Line Results From Phase 3 Focus Trial of Kyprolis in Patients with Relapsed and Advanced Refractory Multiple Myeloma
    • Aug 04, 2014: Amgen Announces Phase 3 ASPIRE Trial of Kyprolis in Patients with Relapsed Multiple Myeloma Met Primary Endpoint
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • Takeda Pharmaceutical Company Limited
      • Clinical Trial Overview of Takeda Pharmaceutical Company Limited
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Johnson & Johnson
      • Clinical Trial Overview of Johnson & Johnson
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
      • Oncotherapeutics
      • Clinical Trial Overview of Oncotherapeutics
      • Janssen Research & Development, LLC
      • Clinical Trial Overview of Janssen Research & Development, LLC
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Mayo Clinic
      • Clinical Trial Overview of Mayo Clinic
      • University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of University of Texas M. D. Anderson Cancer Center
      • University of Arkansas
      • Clinical Trial Overview of University of Arkansas
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • Fondazione Neoplasie Sangue Onlus
      • Clinical Trial Overview of Fondazione Neoplasie Sangue Onlus
      • Washington University School of Medicine
      • Clinical Trial Overview of Washington University School of Medicine
      • Weill Cornell Medical College
      • Clinical Trial Overview of Weill Cornell Medical College
      • Beijing Chao-Yang Hospital
      • Clinical Trial Overview of Beijing Chao-Yang Hospital
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncotherapeutics, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Research & Development, LLC, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas M. D. Anderson Cancer Center, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Arkansas, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione Neoplasie Sangue Onlus, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Weill Cornell Medical College, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Beijing Chao-Yang Hospital, 2014*

List of Figures

  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top